New Horizons in Antifungal Therapy

Journal of Fungi

Kaila M. Pianalto¹  J. Andrew Alspaugh¹ 

[1] Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA;

关键词: amphotericin;    polyene;    azole;    echinocandin;    flucytosine;    aspergillosis;    candidiasis;    cryptococcosis;    fungal infection;    mycosis;   

DOI  :  10.3390/jof2040026

来源: DOAJ

【 摘 要 】

Recent investigations have yielded both profound insights into the mechanisms required by pathogenic fungi for virulence within the human host, as well as novel potential targets for antifungal therapeutics. Some of these studies have resulted in the identification of novel compounds that act against these pathways and also demonstrate potent antifungal activity. However, considerable effort is required to move from pre-clinical compound testing to true clinical trials, a necessary step toward ultimately bringing new drugs to market. The rising incidence of invasive fungal infections mandates continued efforts to identify new strategies for antifungal therapy. Moreover, these life-threatening infections often occur in our most vulnerable patient populations. In addition to finding completely novel antifungal compounds, there is also a renewed effort to redirect existing drugs for use as antifungal agents. Several recent screens have identified potent antifungal activity in compounds previously indicated for other uses in humans. Together, the combined efforts of academic investigators and the pharmaceutical industry is resulting in exciting new possibilities for the treatment of invasive fungal infections.

【 授权许可】

Unknown